Ticagrelor is a reversible, 3rd-generation non-thienopyridine P2Y12 ADPRB, approved for combined antiplatelet therapy in patients with ACS (with or without PCI) and for long-term combined antiplatelet therapy in coronary artery disease (CAD) patients with high ischemic and low bleeding risk [3,40]. This evidence concerns the gene P2RY12 and coronary artery disorder.